Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Waste Management, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Waste Management, Inc. trades at $234.36 (market cap $94.08B). The key difference: Waste Management, Inc. is far larger — about 11.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Waste Management, Inc. pays a 1.51% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | WM | |
|---|---|---|
Market Cap | $8.04B | $94.08B |
Sector | Health | Industrials |
52-Week High | $339.75 | $246.51 |
52-Week Low | $241.71 | $196.77 |
Enterprise Value | $7.85B | $116.81B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
WM trades at $236.71, up 1.45% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages and a consensus analyst price target of $263.57. Recent earnings beat expectations in Q1 2026, with revenue growth to $25.20 billion in 2025. The company maintains solid profitability with a 10.99% net margin and offers a dividend, with the next payment scheduled for June 18, 2026.
Outlook remains positive due to pricing discipline and renewable energy initiatives, but high valuation multiples (P/E 34.26) and recent earnings misses pose risks. Institutional sentiment is bullish with no sell ratings, though debt levels have increased. Key near-term catalyst is Q2 2026 earnings release on July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
